{{Infobox drug
| IUPAC_name = (3''R'',4''R'')-3-(5,6-Dihydro-4''H''-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1''H''-indol-3-yl)-2,5-pyrrolidinedione
| image = Tivantinib structure.svg
| image2 = Tivantinib ball-and-stick model.png
| alt = 
| caption =

<!-- Clinical data -->
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Investigational
| routes_of_administration = Oral

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| onset = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number = 905854-02-6
| ATCvet = 
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 11494412
| ChEMBL = 2103882
| DrugBank = 
| ChemSpiderID = 9669218
| KEGG = D10173
| synonyms = ARQ197; ARQ-197

<!-- Chemical data -->
| C=23|H=19|N=3|O=2
| molecular_weight = 369.42 g/mol
| smiles = C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65
| StdInChI = 1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2, (H,25,27,28)/t19-,20-/m0/s1
| StdInChIKey = UCEQXRCJXIVODC-PMACEKPBSA-N
}}

'''Tivantinib''' ('''ARQ197'''; by [[Arqule]], Inc.) is an experimental small molecule anti-cancer drug. It is a [[bisindolylmaleimide]] that binds to the dephosphorylated [[MET kinase]] ''[[in vitro]]''. (MET is a [[growth factor receptor]].) Tivantinib is being tested clinically as a highly selective [[MET inhibitor]].<ref name="wsj">{{cite web|url=https://online.wsj.com/article/PR-CO-20140204-906777.html|title=ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko Kirin in Japan - WSJ.com|publisher=online.wsj.com|accessdate=2014-02-09}}</ref> However, the mechanism of action of tivantinib is still unclear.{{citation needed|date=January 2015}}

Tivantinib displays cytotoxic activity via molecular mechanisms that are independent from its ability to bind MET, notably tubulin binding, which likely underlies tivantinib cytotoxicity.<ref>{{Cite journal
 | pmid = 23532890
| year = 2013
| author1 = Basilico
| first1 = C
| title = Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET
| journal = Clinical Cancer Research
| volume = 19
| issue = 9
| pages = 2381–92
| last2 = Pennacchietti
| first2 = S
| last3 = Vigna
| first3 = E
| last4 = Chiriaco
| first4 = C
| last5 = Arena
| first5 = S
| last6 = Bardelli
| first6 = A
| last7 = Valdembri
| first7 = D
| last8 = Serini
| first8 = G
| last9 = Michieli
| first9 = P
| doi = 10.1158/1078-0432.CCR-12-3459
}}</ref>

Possible applications include [[non-small-cell lung carcinoma]], [[hepatocellular carcinoma]], and [[oesophageal cancer]].<ref name="Spreitzer">{{cite journal| author = H. Spreitzer| date = 24 November 2014| title = Neue Wirkstoffe – Tivantinib| journal = Österreichische Apothekerzeitung| issue = 24/2014| page = 30| language = German}}</ref>

In 2017, it was announced that a phase III clinical trial for advanced [[hepatocellular carcinoma]] had failed to meet the primary endpoint.<ref>[http://www.genengnews.com/gen-news-highlights/arqule-daiichi-sankyo-say-cancer-candidate-tivantinib-fails-phase-iii-trial/81253902 ArQule, Daiichi Sankyo Say Cancer Candidate Tivantinib Fails Phase III Trial. Feb 2017]</ref><Ref>https://www.arqule.com/pipeline/tivantinib-arq-197/</ref>

==References==
{{reflist}}

==See also==
* [[Template:Intracellular chemotherapeutic agents]]   <!--  {{Intracellular chemotherapeutic agents}}  -->
* [[Template:Growth factor receptor modulators]]      <!--   {{Growth factor receptor modulators}}  -->

[[Category:Bisindolylmaleimides]]
[[Category:Experimental cancer drugs]]
[[Category:Protein kinase inhibitors]]
[[Category:Succinimides]]


{{antineoplastic-drug-stub}}